Our results demonstrated that FGF-23 promotes LOXL2 expression and enhances osteosarcoma cell migration through activation of ERK, p38, and JNK signaling pathways, while simultaneously inhibiting miR-4463 expression. Here, LOXL2 is linked to osteosarcoma.